drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00226 | DB00635 | 1,000 | 1,573 | [
"DDInter845",
"DDInter1515"
] | Guanadrel | Prednisone | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1000,
24,
1573
]
],
[
[
1000,
24,
175
],
[
175,
40,
1573
]
],
[
[
1000,
24,
251
],
[
251,
1,
1573
]
],
[
[
1000,
24,
1148
],
[
1148,
62,
1573
]
],
[
[
1000,
63,
1648
],
[
1648,
24,
1573
]
],
[
[
1000,
24,
473
],
[
473,
63,
1573
]
],
[
[
1000,
25,
1214
],
[
1214,
24,
1573
]
],
[
[
1000,
24,
593
],
[
593,
64,
1573
]
],
[
[
1000,
24,
175
],
[
175,
40,
1581
],
[
1581,
1,
1573
]
],
[
[
1000,
24,
1220
],
[
1220,
1,
175
],
[
175,
40,
1573
]
]
] | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Testolactone"
],
[
"Testolactone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
]
]
] | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Prednisone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Guanadrel may lead to a major life threatening interaction when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Prednisone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Prednisone (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone (Compound) resembles Prednisone (Compound) |
DB00317 | DB11730 | 883 | 351 | [
"DDInter810",
"DDInter1588"
] | Gefitinib | Ribociclib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
883,
24,
351
]
],
[
[
883,
24,
283
],
[
283,
62,
351
]
],
[
[
883,
24,
1627
],
[
1627,
23,
351
]
],
[
[
883,
23,
479
],
[
479,
23,
351
]
],
[
[
883,
63,
288
],
[
288,
24,
351
]
],
[
[
883,
24,
1249
],
[
1249,
24,
351
]
],
[
[
883,
24,
1654
],
[
1654,
63,
351
]
],
[
[
883,
23,
211
],
[
211,
24,
351
]
],
[
[
883,
40,
1195
],
[
1195,
24,
351
]
],
[
[
883,
24,
129
],
[
129,
25,
351
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gefitinib (Compound) resembles Erlotinib (Compound) and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib |
DB00978 | DB08868 | 739 | 1,011 | [
"DDInter1084",
"DDInter737"
] | Lomefloxacin | Fingolimod | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
739,
25,
1011
]
],
[
[
739,
21,
29097
],
[
29097,
60,
1011
]
],
[
[
739,
62,
112
],
[
112,
23,
1011
]
],
[
[
739,
24,
144
],
[
144,
63,
1011
]
],
[
[
739,
24,
480
],
[
480,
24,
1011
]
],
[
[
739,
63,
455
],
[
455,
24,
1011
]
],
[
[
739,
23,
973
],
[
973,
25,
1011
]
],
[
[
739,
24,
129
],
[
129,
64,
1011
]
],
[
[
739,
64,
175
],
[
175,
25,
1011
]
],
[
[
739,
25,
1154
],
[
1154,
25,
1011
]
]
] | [
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Eye pain"
],
[
"Eye pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Lomefloxacin (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Fingolimod (Compound)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel and Paclitaxel may lead to a major life threatening interaction when taken with Fingolimod
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Fingolimod
Lomefloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may lead to a major life threatening interaction when taken with Fingolimod
Lomefloxacin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Fingolimod |
DB06603 | DB08816 | 39 | 578 | [
"DDInter1387",
"DDInter1802"
] | Panobinostat | Ticagrelor | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
39,
24,
578
]
],
[
[
39,
63,
336
],
[
336,
23,
578
]
],
[
[
39,
64,
17
],
[
17,
23,
578
]
],
[
[
39,
25,
1011
],
[
1011,
62,
578
]
],
[
[
39,
64,
1578
],
[
1578,
24,
578
]
],
[
[
39,
63,
723
],
[
723,
24,
578
]
],
[
[
39,
25,
868
],
[
868,
63,
578
]
],
[
[
39,
24,
1094
],
[
1094,
63,
578
]
],
[
[
39,
25,
397
],
[
397,
24,
578
]
],
[
[
39,
24,
1623
],
[
1623,
24,
578
]
]
] | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plicamycin"
],
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
]
] | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Panobinostat may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Panobinostat may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Panobinostat may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Panobinostat may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Panobinostat may lead to a major life threatening interaction when taken with Plicamycin and Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB00443 | DB10316 | 251 | 334 | [
"DDInter195",
"DDInter1248"
] | Betamethasone | Mumps virus strain B level jeryl lynn live antigen | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
251,
25,
334
]
],
[
[
251,
1,
617
],
[
617,
24,
334
]
],
[
[
251,
64,
1057
],
[
1057,
25,
334
]
],
[
[
251,
24,
1316
],
[
1316,
64,
334
]
],
[
[
251,
25,
908
],
[
908,
25,
334
]
],
[
[
251,
24,
629
],
[
629,
25,
334
]
],
[
[
251,
63,
599
],
[
599,
25,
334
]
],
[
[
251,
40,
870
],
[
870,
25,
334
]
],
[
[
251,
25,
1259
],
[
1259,
64,
334
]
],
[
[
251,
1,
1220
],
[
1220,
25,
334
]
]
] | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
],
[
"Durvalumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
]
] | Betamethasone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Betamethasone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen |
DB00982 | DB01017 | 1,517 | 1,669 | [
"DDInter991",
"DDInter1224"
] | Isotretinoin | Minocycline | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-containing product was FDA approved on 7 May 1982. | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971. | Major | 2 | [
[
[
1517,
25,
1669
]
],
[
[
1517,
64,
1572
],
[
1572,
1,
1669
]
],
[
[
1517,
64,
1545
],
[
1545,
40,
1669
]
],
[
[
1517,
7,
5057
],
[
5057,
45,
1669
]
],
[
[
1517,
63,
663
],
[
663,
24,
1669
]
],
[
[
1517,
24,
279
],
[
279,
63,
1669
]
],
[
[
1517,
25,
990
],
[
990,
64,
1669
]
],
[
[
1517,
64,
640
],
[
640,
25,
1669
]
],
[
[
1517,
64,
1572
],
[
1572,
40,
964
],
[
964,
1,
1669
]
],
[
[
1517,
64,
964
],
[
964,
1,
1572
],
[
1572,
1,
1669
]
]
] | [
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} (Compound) upregulates {v} (Gene)",
"IL1B"
],
[
"IL1B",
"{u} (Gene) is bound by {v} (Compound)",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
]
] | Isotretinoin may lead to a major life threatening interaction when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Isotretinoin may lead to a major life threatening interaction when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Minocycline (Compound)
Isotretinoin (Compound) upregulates IL1B (Gene) and IL1B (Gene) is bound by Minocycline (Compound)
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Isotretinoin may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Minocycline
Isotretinoin may lead to a major life threatening interaction when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Minocycline
Isotretinoin may lead to a major life threatening interaction when taken with Demeclocycline and Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline (Compound) resembles Minocycline (Compound)
Isotretinoin may lead to a major life threatening interaction when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Minocycline (Compound) |
DB00708 | DB00757 | 1,454 | 1,166 | [
"DDInter1718",
"DDInter581"
] | Sufentanil | Dolasetron | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Major | 2 | [
[
[
1454,
25,
1166
]
],
[
[
1454,
63,
19
],
[
19,
40,
1166
]
],
[
[
1454,
63,
85
],
[
85,
1,
1166
]
],
[
[
1454,
6,
8374
],
[
8374,
45,
1166
]
],
[
[
1454,
21,
28841
],
[
28841,
60,
1166
]
],
[
[
1454,
63,
752
],
[
752,
23,
1166
]
],
[
[
1454,
24,
214
],
[
214,
63,
1166
]
],
[
[
1454,
63,
475
],
[
475,
24,
1166
]
],
[
[
1454,
24,
1619
],
[
1619,
64,
1166
]
],
[
[
1454,
25,
222
],
[
222,
64,
1166
]
]
] | [
[
[
"Sufentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} (Compound) resembles {v} (Compound)",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} (Compound) resembles {v} (Compound)",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchospasm"
],
[
"Bronchospasm",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Sufentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
]
] | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound)
Sufentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dolasetron (Compound)
Sufentanil (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Dolasetron (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolasetron
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Dolasetron
Sufentanil may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dolasetron |
DB08889 | DB08904 | 350 | 375 | [
"DDInter299",
"DDInter342"
] | Carfilzomib | Certolizumab pegol | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
350,
25,
375
]
],
[
[
350,
63,
1461
],
[
1461,
23,
375
]
],
[
[
350,
63,
231
],
[
231,
24,
375
]
],
[
[
350,
24,
200
],
[
200,
63,
375
]
],
[
[
350,
64,
1336
],
[
1336,
24,
375
]
],
[
[
350,
25,
517
],
[
517,
63,
375
]
],
[
[
350,
64,
1066
],
[
1066,
25,
375
]
],
[
[
350,
63,
63
],
[
63,
25,
375
]
],
[
[
350,
24,
1330
],
[
1330,
64,
375
]
],
[
[
350,
25,
1624
],
[
1624,
64,
375
]
]
] | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
],
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carfilzomib may lead to a major life threatening interaction when taken with Etonogestrel and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carfilzomib may lead to a major life threatening interaction when taken with Norgestrel and Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carfilzomib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may lead to a major life threatening interaction when taken with Certolizumab pegol
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Certolizumab pegol
Carfilzomib may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00539 | DB00557 | 11 | 252 | [
"DDInter1837",
"DDInter895"
] | Toremifene | Hydroxyzine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Major | 2 | [
[
[
11,
25,
252
]
],
[
[
11,
25,
851
],
[
851,
1,
252
]
],
[
[
11,
1,
11296
],
[
11296,
1,
252
]
],
[
[
11,
25,
623
],
[
623,
40,
252
]
],
[
[
11,
21,
28787
],
[
28787,
60,
252
]
],
[
[
11,
63,
752
],
[
752,
23,
252
]
],
[
[
11,
23,
112
],
[
112,
62,
252
]
],
[
[
11,
64,
1181
],
[
1181,
24,
252
]
],
[
[
11,
25,
820
],
[
820,
63,
252
]
],
[
[
11,
24,
720
],
[
720,
63,
252
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Bromodiphenhydramine"
],
[
"Bromodiphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
]
] | Toremifene may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Toremifene (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Hydroxyzine (Compound)
Toremifene may lead to a major life threatening interaction when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound)
Toremifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Hydroxyzine (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Hydroxyzine
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Hydroxyzine
Toremifene may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Toremifene may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine |
DB11760 | DB11828 | 119 | 1,406 | [
"DDInter1742",
"DDInter1281"
] | Talazoparib | Neratinib | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
119,
24,
1406
]
],
[
[
119,
63,
392
],
[
392,
24,
1406
]
],
[
[
119,
64,
1510
],
[
1510,
24,
1406
]
],
[
[
119,
24,
1619
],
[
1619,
63,
1406
]
],
[
[
119,
24,
738
],
[
738,
24,
1406
]
],
[
[
119,
63,
1593
],
[
1593,
25,
1406
]
],
[
[
119,
64,
609
],
[
609,
25,
1406
]
],
[
[
119,
24,
1339
],
[
1339,
64,
1406
]
],
[
[
119,
63,
392
],
[
392,
23,
1135
],
[
1135,
23,
1406
]
],
[
[
119,
64,
1510
],
[
1510,
64,
392
],
[
392,
24,
1406
]
]
] | [
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neratinib"
]
],
[
[
"Talazoparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
]
] | Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Talazoparib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Talazoparib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may lead to a major life threatening interaction when taken with Neratinib
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Talazoparib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib |
DB09073 | DB11837 | 951 | 1,297 | [
"DDInter1379",
"DDInter1351"
] | Palbociclib | Osilodrostat | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Moderate | 1 | [
[
[
951,
24,
1297
]
],
[
[
951,
23,
907
],
[
907,
62,
1297
]
],
[
[
951,
62,
271
],
[
271,
23,
1297
]
],
[
[
951,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
951,
63,
353
],
[
353,
24,
1297
]
],
[
[
951,
62,
479
],
[
479,
24,
1297
]
],
[
[
951,
24,
321
],
[
321,
24,
1297
]
],
[
[
951,
64,
976
],
[
976,
24,
1297
]
],
[
[
951,
25,
1339
],
[
1339,
63,
1297
]
],
[
[
951,
24,
351
],
[
351,
25,
1297
]
]
] | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
],
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
]
] | Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Palbociclib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Palbociclib may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osilodrostat |
DB00501 | DB01175 | 752 | 318 | [
"DDInter380",
"DDInter672"
] | Cimetidine | Escitalopram | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Moderate | 1 | [
[
[
752,
24,
318
]
],
[
[
752,
64,
1230
],
[
1230,
1,
318
]
],
[
[
752,
6,
8374
],
[
8374,
45,
318
]
],
[
[
752,
18,
6351
],
[
6351,
57,
318
]
],
[
[
752,
21,
29310
],
[
29310,
60,
318
]
],
[
[
752,
24,
1478
],
[
1478,
62,
318
]
],
[
[
752,
24,
723
],
[
723,
23,
318
]
],
[
[
752,
23,
112
],
[
112,
23,
318
]
],
[
[
752,
63,
245
],
[
245,
24,
318
]
],
[
[
752,
24,
473
],
[
473,
24,
318
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} (Compound) downregulates {v} (Gene)",
"COTL1"
],
[
"COTL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Toxic epidermal necrolysis"
],
[
"Toxic epidermal necrolysis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
]
] | Cimetidine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Cimetidine (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Escitalopram (Compound)
Cimetidine (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Escitalopram (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram |
DB00215 | DB00549 | 1,230 | 522 | [
"DDInter388",
"DDInter1955"
] | Citalopram | Zafirlukast | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Minor | 0 | [
[
[
1230,
23,
522
]
],
[
[
1230,
6,
7950
],
[
7950,
45,
522
]
],
[
[
1230,
21,
28935
],
[
28935,
60,
522
]
],
[
[
1230,
25,
222
],
[
222,
62,
522
]
],
[
[
1230,
1,
318
],
[
318,
62,
522
]
],
[
[
1230,
24,
1347
],
[
1347,
62,
522
]
],
[
[
1230,
62,
168
],
[
168,
24,
522
]
],
[
[
1230,
25,
1487
],
[
1487,
63,
522
]
],
[
[
1230,
24,
1604
],
[
1604,
63,
522
]
],
[
[
1230,
23,
723
],
[
723,
63,
522
]
]
] | [
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperbilirubinaemia"
],
[
"Hyperbilirubinaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
]
] | Citalopram (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zafirlukast (Compound)
Citalopram (Compound) causes Hyperbilirubinaemia (Side Effect) and Hyperbilirubinaemia (Side Effect) is caused by Zafirlukast (Compound)
Citalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Citalopram (Compound) resembles Escitalopram (Compound) and Es
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Citalopram may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Citalopram may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast |
DB01156 | DB08815 | 593 | 154 | [
"DDInter252",
"DDInter1104"
] | Bupropion | Lurasidone | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Major | 2 | [
[
[
593,
25,
154
]
],
[
[
593,
6,
8374
],
[
8374,
45,
154
]
],
[
[
593,
21,
28963
],
[
28963,
60,
154
]
],
[
[
593,
24,
1033
],
[
1033,
63,
154
]
],
[
[
593,
24,
1532
],
[
1532,
24,
154
]
],
[
[
593,
63,
1242
],
[
1242,
24,
154
]
],
[
[
593,
64,
401
],
[
401,
24,
154
]
],
[
[
593,
25,
1220
],
[
1220,
24,
154
]
],
[
[
593,
62,
752
],
[
752,
24,
154
]
],
[
[
593,
25,
407
],
[
407,
63,
154
]
]
] | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
]
] | Bupropion (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Bupropion (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Bupropion may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Bupropion may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Bupropion may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Bupropion may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone |
DB01246 | DB01364 | 820 | 22 | [
"DDInter45",
"DDInter650"
] | Alimemazine | Ephedrine | A phenothiazine derivative that is used as an antipruritic. | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine from storage vesicles.[A193650,L12972] Ephedrine is used for its vasoconstrictive, positive chronotropic, and positive inotropic effects. Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists.[A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016. | Moderate | 1 | [
[
[
820,
24,
22
]
],
[
[
820,
63,
80
],
[
80,
24,
22
]
],
[
[
820,
24,
1529
],
[
1529,
63,
22
]
],
[
[
820,
18,
1954
],
[
1954,
57,
22
]
],
[
[
820,
21,
28680
],
[
28680,
60,
22
]
],
[
[
820,
63,
475
],
[
475,
23,
22
]
],
[
[
820,
40,
508
],
[
508,
24,
22
]
],
[
[
820,
1,
146
],
[
146,
24,
22
]
],
[
[
820,
24,
1021
],
[
1021,
24,
22
]
],
[
[
820,
74,
216
],
[
216,
24,
22
]
]
] | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} (Compound) downregulates {v} (Gene)",
"COG2"
],
[
"COG2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
]
] | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Alimemazine (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Ephedrine (Compound)
Alimemazine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Ephedrine (Compound)
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Alimemazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Alimemazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Alimemazine (Compound) resembles Chlorpromazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine |
DB00722 | DB09104 | 743 | 286 | [
"DDInter1079",
"DDInter1118"
] | Lisinopril | Magnesium hydroxide | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Minor | 0 | [
[
[
743,
23,
286
]
],
[
[
743,
24,
820
],
[
820,
23,
286
]
],
[
[
743,
1,
610
],
[
610,
23,
286
]
],
[
[
743,
63,
999
],
[
999,
23,
286
]
],
[
[
743,
40,
1638
],
[
1638,
23,
286
]
],
[
[
743,
1,
633
],
[
633,
24,
286
]
],
[
[
743,
23,
1283
],
[
1283,
24,
286
]
],
[
[
743,
24,
891
],
[
891,
24,
286
]
],
[
[
743,
24,
1019
],
[
1019,
63,
286
]
],
[
[
743,
63,
251
],
[
251,
24,
286
]
]
] | [
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
]
] | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lisinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lisinopril (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB00808 | DB11827 | 1,605 | 433 | [
"DDInter916",
"DDInter669"
] | Indapamide | Ertugliflozin | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1605,
24,
433
]
],
[
[
1605,
40,
811
],
[
811,
24,
433
]
],
[
[
1605,
24,
959
],
[
959,
24,
433
]
],
[
[
1605,
63,
251
],
[
251,
24,
433
]
],
[
[
1605,
24,
1019
],
[
1019,
63,
433
]
],
[
[
1605,
40,
811
],
[
811,
24,
959
],
[
959,
24,
433
]
],
[
[
1605,
24,
959
],
[
959,
62,
1103
],
[
1103,
23,
433
]
],
[
[
1605,
63,
251
],
[
251,
40,
1103
],
[
1103,
23,
433
]
],
[
[
1605,
63,
870
],
[
870,
1,
1103
],
[
1103,
23,
433
]
],
[
[
1605,
24,
820
],
[
820,
63,
1020
],
[
1020,
24,
433
]
]
] | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
]
] | Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin |
DB00457 | DB00620 | 1,205 | 175 | [
"DDInter1511",
"DDInter1855"
] | Prazosin | Triamcinolone | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624] | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis. | Moderate | 1 | [
[
[
1205,
24,
175
]
],
[
[
1205,
24,
1573
],
[
1573,
1,
175
]
],
[
[
1205,
24,
617
],
[
617,
40,
175
]
],
[
[
1205,
63,
251
],
[
251,
1,
175
]
],
[
[
1205,
7,
16662
],
[
16662,
46,
175
]
],
[
[
1205,
21,
28762
],
[
28762,
60,
175
]
],
[
[
1205,
24,
1274
],
[
1274,
63,
175
]
],
[
[
1205,
24,
1512
],
[
1512,
24,
175
]
],
[
[
1205,
40,
1433
],
[
1433,
24,
175
]
],
[
[
1205,
40,
195
],
[
195,
63,
175
]
]
] | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} (Compound) upregulates {v} (Gene)",
"SQRDL"
],
[
"SQRDL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
],
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Terazosin"
],
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
]
] | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compound)
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Triamcinolone (Compound)
Prazosin (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Triamcinolone (Compound)
Prazosin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Triamcinolone (Compound)
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Prazosin (Compound) resembles Doxazosin (Compound) and Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Prazosin (Compound) resembles Terazosin (Compound) and Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone |
DB00261 | DB00529 | 702 | 789 | [
"DDInter93",
"DDInter779"
] | Anagrelide | Foscarnet | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Major | 2 | [
[
[
702,
25,
789
]
],
[
[
702,
21,
28873
],
[
28873,
60,
789
]
],
[
[
702,
23,
112
],
[
112,
62,
789
]
],
[
[
702,
25,
1494
],
[
1494,
24,
789
]
],
[
[
702,
24,
770
],
[
770,
63,
789
]
],
[
[
702,
25,
823
],
[
823,
63,
789
]
],
[
[
702,
64,
521
],
[
521,
24,
789
]
],
[
[
702,
25,
877
],
[
877,
64,
789
]
],
[
[
702,
21,
28873
],
[
28873,
60,
112
],
[
112,
62,
789
]
],
[
[
702,
21,
29106
],
[
29106,
60,
1494
],
[
1494,
24,
789
]
]
] | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Foscarnet"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Myalgia"
],
[
"Myalgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
]
] | Anagrelide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Foscarnet (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Foscarnet
Anagrelide may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Anagrelide may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Anagrelide may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Foscarnet
Anagrelide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Foscarnet
Anagrelide (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Palonosetron (Compound) and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet |
DB06697 | DB08873 | 436 | 74 | [
"DDInter121",
"DDInter221"
] | Artemether | Boceprevir | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Major | 2 | [
[
[
436,
25,
74
]
],
[
[
436,
6,
8374
],
[
8374,
45,
74
]
],
[
[
436,
63,
86
],
[
86,
24,
74
]
],
[
[
436,
25,
384
],
[
384,
63,
74
]
],
[
[
436,
24,
1040
],
[
1040,
63,
74
]
],
[
[
436,
64,
609
],
[
609,
24,
74
]
],
[
[
436,
25,
129
],
[
129,
64,
74
]
],
[
[
436,
24,
283
],
[
283,
64,
74
]
],
[
[
436,
24,
1478
],
[
1478,
25,
74
]
],
[
[
436,
63,
303
],
[
303,
25,
74
]
]
] | [
[
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
]
] | Artemether (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Artemether may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Artemether may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Artemether may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Boceprevir
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Boceprevir
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Boceprevir
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Boceprevir |
DB00323 | DB11130 | 1,062 | 407 | [
"DDInter1829",
"DDInter1344"
] | Tolcapone | Opium | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
1062,
24,
407
]
],
[
[
1062,
24,
662
],
[
662,
24,
407
]
],
[
[
1062,
63,
475
],
[
475,
24,
407
]
],
[
[
1062,
24,
1609
],
[
1609,
63,
407
]
],
[
[
1062,
1,
1533
],
[
1533,
24,
407
]
],
[
[
1062,
25,
1053
],
[
1053,
25,
407
]
],
[
[
1062,
24,
267
],
[
267,
25,
407
]
],
[
[
1062,
24,
662
],
[
662,
63,
558
],
[
558,
24,
407
]
],
[
[
1062,
24,
104
],
[
104,
24,
409
],
[
409,
24,
407
]
],
[
[
1062,
63,
475
],
[
475,
24,
409
],
[
409,
24,
407
]
]
] | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} (Compound) resembles {v} (Compound)",
"Entacapone"
],
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tolcapone (Compound) resembles Entacapone (Compound) and Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tolcapone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opium
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may lead to a major life threatening interaction when taken with Opium
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB00704 | DB12010 | 267 | 214 | [
"DDInter1263",
"DDInter785"
] | Naltrexone | Fostamatinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
267,
24,
214
]
],
[
[
267,
24,
866
],
[
866,
24,
214
]
],
[
[
267,
63,
322
],
[
322,
24,
214
]
],
[
[
267,
25,
1322
],
[
1322,
24,
214
]
],
[
[
267,
64,
576
],
[
576,
24,
214
]
],
[
[
267,
24,
159
],
[
159,
63,
214
]
],
[
[
267,
25,
180
],
[
180,
63,
214
]
],
[
[
267,
24,
609
],
[
609,
25,
214
]
],
[
[
267,
25,
990
],
[
990,
25,
214
]
],
[
[
267,
63,
1236
],
[
1236,
25,
214
]
]
] | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Naltrexone may lead to a major life threatening interaction when taken with Alfentanil and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Naltrexone may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Naltrexone may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Naltrexone may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Fostamatinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may lead to a major life threatening interaction when taken with Fostamatinib |
DB00490 | DB01041 | 946 | 770 | [
"DDInter254",
"DDInter1789"
] | Buspirone | Thalidomide | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
946,
24,
770
]
],
[
[
946,
6,
7524
],
[
7524,
45,
770
]
],
[
[
946,
21,
29177
],
[
29177,
60,
770
]
],
[
[
946,
24,
609
],
[
609,
63,
770
]
],
[
[
946,
63,
1614
],
[
1614,
24,
770
]
],
[
[
946,
64,
1494
],
[
1494,
24,
770
]
],
[
[
946,
24,
104
],
[
104,
24,
770
]
],
[
[
946,
25,
1264
],
[
1264,
63,
770
]
],
[
[
946,
25,
1166
],
[
1166,
24,
770
]
],
[
[
946,
24,
1220
],
[
1220,
64,
770
]
]
] | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal stiffness"
],
[
"Musculoskeletal stiffness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
]
] | Buspirone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Buspirone (Compound) causes Musculoskeletal stiffness (Side Effect) and Musculoskeletal stiffness (Side Effect) is caused by Thalidomide (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Buspirone may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Buspirone may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Buspirone may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Thalidomide |
DB08904 | DB09115 | 375 | 505 | [
"DDInter342",
"DDInter559"
] | Certolizumab pegol | Diiodohydroxyquinoline | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
375,
24,
505
]
],
[
[
375,
63,
1593
],
[
1593,
24,
505
]
],
[
[
375,
64,
908
],
[
908,
24,
505
]
],
[
[
375,
24,
1434
],
[
1434,
63,
505
]
],
[
[
375,
25,
1480
],
[
1480,
63,
505
]
],
[
[
375,
63,
1593
],
[
1593,
63,
467
],
[
467,
24,
505
]
],
[
[
375,
63,
467
],
[
467,
24,
1593
],
[
1593,
24,
505
]
],
[
[
375,
64,
908
],
[
908,
24,
1593
],
[
1593,
24,
505
]
],
[
[
375,
64,
1510
],
[
1510,
64,
1593
],
[
1593,
24,
505
]
],
[
[
375,
64,
1377
],
[
1377,
25,
1593
],
[
1593,
24,
505
]
]
] | [
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
],
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
]
] | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Certolizumab pegol may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline |
DB01229 | DB08881 | 973 | 868 | [
"DDInter1377",
"DDInter1925"
] | Paclitaxel | Vemurafenib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Moderate | 1 | [
[
[
973,
24,
868
]
],
[
[
973,
6,
8374
],
[
8374,
45,
868
]
],
[
[
973,
7,
4943
],
[
4943,
46,
868
]
],
[
[
973,
18,
9440
],
[
9440,
46,
868
]
],
[
[
973,
7,
20003
],
[
20003,
57,
868
]
],
[
[
973,
18,
12106
],
[
12106,
57,
868
]
],
[
[
973,
6,
5816
],
[
5816,
57,
868
]
],
[
[
973,
34,
16974
],
[
16974,
57,
868
]
],
[
[
973,
21,
28847
],
[
28847,
60,
868
]
],
[
[
973,
63,
112
],
[
112,
23,
868
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) upregulates {v} (Gene)",
"GRB10"
],
[
"GRB10",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) downregulates {v} (Gene)",
"CRTAP"
],
[
"CRTAP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) upregulates {v} (Gene)",
"NOSIP"
],
[
"NOSIP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) downregulates {v} (Gene)",
"NT5DC2"
],
[
"NT5DC2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"TUBB4B"
],
[
"TUBB4B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
]
] | Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Paclitaxel (Compound) upregulates GRB10 (Gene) and GRB10 (Gene) is upregulated by Vemurafenib (Compound)
Paclitaxel (Compound) downregulates CRTAP (Gene) and CRTAP (Gene) is upregulated by Vemurafenib (Compound)
Paclitaxel (Compound) upregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Vemurafenib (Compound)
Paclitaxel (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Vemurafenib (Compound)
Paclitaxel (Compound) binds TUBB4B (Gene) and TUBB4B (Gene) is downregulated by Vemurafenib (Compound)
Paclitaxel (Compound) binds TUBB6 (Gene) and Paclitaxel (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Vemurafenib (Compound)
Paclitaxel (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib |
DB06168 | DB08871 | 1,531 | 36 | [
"DDInter281",
"DDInter666"
] | Canakinumab | Eribulin | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors . | Moderate | 1 | [
[
[
1531,
24,
36
]
],
[
[
1531,
24,
221
],
[
221,
63,
36
]
],
[
[
1531,
63,
1463
],
[
1463,
24,
36
]
],
[
[
1531,
62,
1461
],
[
1461,
24,
36
]
],
[
[
1531,
24,
1430
],
[
1430,
24,
36
]
],
[
[
1531,
25,
980
],
[
980,
24,
36
]
],
[
[
1531,
25,
1510
],
[
1510,
64,
36
]
],
[
[
1531,
63,
494
],
[
494,
25,
36
]
],
[
[
1531,
25,
1011
],
[
1011,
25,
36
]
],
[
[
1531,
64,
1064
],
[
1064,
25,
36
]
]
] | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
],
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
]
] | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Canakinumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Eribulin
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Eribulin
Canakinumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Eribulin
Canakinumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Eribulin |
DB00514 | DB01168 | 506 | 1,053 | [
"DDInter527",
"DDInter1526"
] | Dextromethorphan | Procarbazine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
506,
25,
1053
]
],
[
[
506,
21,
28898
],
[
28898,
60,
1053
]
],
[
[
506,
25,
9
],
[
9,
63,
1053
]
],
[
[
506,
24,
100
],
[
100,
24,
1053
]
],
[
[
506,
24,
830
],
[
830,
63,
1053
]
],
[
[
506,
63,
701
],
[
701,
24,
1053
]
],
[
[
506,
25,
768
],
[
768,
64,
1053
]
],
[
[
506,
64,
1100
],
[
1100,
25,
1053
]
],
[
[
506,
63,
73
],
[
73,
25,
1053
]
],
[
[
506,
25,
827
],
[
827,
25,
1053
]
]
] | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
],
[
"Tapentadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
]
] | Dextromethorphan (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Procarbazine (Compound)
Dextromethorphan may lead to a major life threatening interaction when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Dextromethorphan may lead to a major life threatening interaction when taken with Tapentadol and Tapentadol may lead to a major life threatening interaction when taken with Procarbazine
Dextromethorphan may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may lead to a major life threatening interaction when taken with Procarbazine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Procarbazine
Dextromethorphan may lead to a major life threatening interaction when taken with Trazodone and Trazodone may lead to a major life threatening interaction when taken with Procarbazine |
DB01234 | DB01764 | 1,220 | 805 | [
"DDInter513",
"DDInter469"
] | Dexamethasone | Dalfopristin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. | Moderate | 1 | [
[
[
1220,
24,
805
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1220,
63,
1101
],
[
1101,
23,
805
]
],
[
[
1220,
25,
283
],
[
283,
62,
805
]
],
[
[
1220,
24,
1618
],
[
1618,
63,
805
]
],
[
[
1220,
63,
609
],
[
609,
24,
805
]
],
[
[
1220,
25,
478
],
[
478,
63,
805
]
],
[
[
1220,
40,
870
],
[
870,
24,
805
]
],
[
[
1220,
1,
175
],
[
175,
24,
805
]
],
[
[
1220,
64,
11
],
[
11,
24,
805
]
]
] | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
]
] | Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Dexamethasone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Dexamethasone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Dexamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Dexamethasone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin |
DB00374 | DB10675 | 1,061 | 961 | [
"DDInter1852",
"DDInter1065"
] | Treprostinil | Licorice | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1061,
24,
961
]
],
[
[
1061,
1,
885
],
[
885,
24,
961
]
],
[
[
1061,
24,
1637
],
[
1637,
24,
961
]
],
[
[
1061,
63,
1214
],
[
1214,
24,
961
]
],
[
[
1061,
1,
885
],
[
885,
24,
1637
],
[
1637,
24,
961
]
],
[
[
1061,
24,
1637
],
[
1637,
63,
885
],
[
885,
24,
961
]
],
[
[
1061,
24,
274
],
[
274,
24,
885
],
[
885,
24,
961
]
],
[
[
1061,
63,
1214
],
[
1214,
24,
870
],
[
870,
24,
961
]
],
[
[
1061,
1,
885
],
[
885,
63,
274
],
[
274,
24,
961
]
],
[
[
1061,
21,
29543
],
[
29543,
60,
870
],
[
870,
24,
961
]
]
] | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Treprostinil",
"{u} (Compound) causes {v} (Side Effect)",
"Contusion"
],
[
"Contusion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
]
] | Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Treprostinil (Compound) causes Contusion (Side Effect) and Contusion (Side Effect) is caused by Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice |
DB08875 | DB09078 | 1,618 | 1,228 | [
"DDInter262",
"DDInter1036"
] | Cabozantinib | Lenvatinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Major | 2 | [
[
[
1618,
25,
1228
]
],
[
[
1618,
62,
112
],
[
112,
23,
1228
]
],
[
[
1618,
64,
463
],
[
463,
23,
1228
]
],
[
[
1618,
64,
1100
],
[
1100,
24,
1228
]
],
[
[
1618,
25,
938
],
[
938,
63,
1228
]
],
[
[
1618,
24,
384
],
[
384,
24,
1228
]
],
[
[
1618,
24,
603
],
[
603,
63,
1228
]
],
[
[
1618,
63,
543
],
[
543,
24,
1228
]
],
[
[
1618,
25,
129
],
[
129,
24,
1228
]
],
[
[
1618,
64,
1069
],
[
1069,
25,
1228
]
]
] | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
] | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Cabozantinib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Cabozantinib may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Cabozantinib may lead to a major life threatening interaction when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Cabozantinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Cabozantinib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib |
DB00108 | DB08885 | 1,066 | 363 | [
"DDInter1268",
"DDInter33"
] | Natalizumab | Aflibercept | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain.[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor. However, it lacks the intracellular structure to propagate subsequent signal transduction, thus essentially sequestering the ligands to prevent activation of VEGFR.[A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in August 2012 and February 2013, respectively.[L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy in August 2023. An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. | Major | 2 | [
[
[
1066,
25,
363
]
],
[
[
1066,
25,
1531
],
[
1531,
24,
363
]
],
[
[
1066,
24,
151
],
[
151,
63,
363
]
],
[
[
1066,
64,
58
],
[
58,
24,
363
]
],
[
[
1066,
25,
384
],
[
384,
63,
363
]
],
[
[
1066,
24,
1136
],
[
1136,
24,
363
]
],
[
[
1066,
64,
1057
],
[
1057,
25,
363
]
],
[
[
1066,
25,
375
],
[
375,
64,
363
]
],
[
[
1066,
25,
1064
],
[
1064,
25,
363
]
],
[
[
1066,
25,
1531
],
[
1531,
24,
151
],
[
151,
63,
363
]
]
] | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
],
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
],
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
]
] | Natalizumab may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Natalizumab may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Natalizumab may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Natalizumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Aflibercept
Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Aflibercept
Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Aflibercept
Natalizumab may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept |
DB01229 | DB11932 | 973 | 327 | [
"DDInter1378",
"DDInter3"
] | Paclitaxel (protein-bound) | Abametapir (topical) | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
973,
24,
327
]
],
[
[
973,
63,
168
],
[
168,
24,
327
]
],
[
[
973,
24,
283
],
[
283,
63,
327
]
],
[
[
973,
24,
868
],
[
868,
24,
327
]
],
[
[
973,
25,
976
],
[
976,
24,
327
]
],
[
[
973,
25,
676
],
[
676,
63,
327
]
],
[
[
973,
63,
168
],
[
168,
24,
283
],
[
283,
63,
327
]
],
[
[
973,
24,
283
],
[
283,
63,
124
],
[
124,
63,
327
]
],
[
[
973,
24,
868
],
[
868,
25,
124
],
[
124,
63,
327
]
],
[
[
973,
24,
309
],
[
309,
63,
168
],
[
168,
24,
327
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir |
DB06694 | DB11823 | 31 | 858 | [
"DDInter1952",
"DDInter673"
] | Xylometazoline (nasal) | Esketamine | Xylometazoline is an alkylbenzene. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect. | Moderate | 1 | [
[
[
31,
24,
858
]
],
[
[
31,
24,
1629
],
[
1629,
25,
858
]
],
[
[
31,
6,
5700
],
[
5700,
45,
1264
],
[
1264,
24,
858
]
],
[
[
31,
24,
1629
],
[
1629,
64,
506
],
[
506,
24,
858
]
],
[
[
31,
24,
1629
],
[
1629,
63,
1311
],
[
1311,
24,
858
]
],
[
[
31,
24,
1629
],
[
1629,
76,
1090
],
[
1090,
24,
858
]
],
[
[
31,
18,
2976
],
[
2976,
57,
1532
],
[
1532,
24,
858
]
],
[
[
31,
24,
1629
],
[
1629,
25,
407
],
[
407,
24,
858
]
],
[
[
31,
24,
1629
],
[
1629,
64,
73
],
[
73,
25,
858
]
],
[
[
31,
63,
87
],
[
87,
63,
530
],
[
530,
24,
858
]
]
] | [
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} (Compound) binds {v} (Gene)",
"ADRA1D"
],
[
"ADRA1D",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Tetryzoline"
],
[
"Tetryzoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} (Compound) downregulates {v} (Gene)",
"STUB1"
],
[
"STUB1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esketamine"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
]
] | Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Esketamine
Xylometazoline (Compound) binds ADRA1D (Gene) and ADRA1D (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Methylene blue may lead to a major life threatening interaction when taken with Tetryzoline and Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Esketamine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Esketamine |
DB00690 | DB01211 | 1,216 | 609 | [
"DDInter762",
"DDInter393"
] | Flurazepam | Clarithromycin | A benzodiazepine derivative used mainly as a hypnotic. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
1216,
24,
609
]
],
[
[
1216,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1216,
21,
28779
],
[
28779,
60,
609
]
],
[
[
1216,
24,
222
],
[
222,
23,
609
]
],
[
[
1216,
63,
752
],
[
752,
23,
609
]
],
[
[
1216,
24,
770
],
[
770,
24,
609
]
],
[
[
1216,
24,
913
],
[
913,
63,
609
]
],
[
[
1216,
40,
523
],
[
523,
24,
609
]
],
[
[
1216,
1,
481
],
[
481,
63,
609
]
],
[
[
1216,
63,
1419
],
[
1419,
24,
609
]
]
] | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Flurazepam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Flurazepam (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Clarithromycin (Compound)
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Flurazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Flurazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00489 | DB08946 | 17 | 512 | [
"DDInter1704",
"DDInter962"
] | Sotalol | Iopanoic acid | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Moderate | 1 | [
[
[
17,
24,
512
]
],
[
[
17,
24,
1106
],
[
1106,
24,
512
]
],
[
[
17,
1,
88
],
[
88,
24,
512
]
],
[
[
17,
24,
777
],
[
777,
63,
512
]
],
[
[
17,
63,
1648
],
[
1648,
24,
512
]
],
[
[
17,
24,
1106
],
[
1106,
63,
1592
],
[
1592,
24,
512
]
],
[
[
17,
1,
88
],
[
88,
24,
1106
],
[
1106,
24,
512
]
],
[
[
17,
63,
1648
],
[
1648,
24,
1428
],
[
1428,
24,
512
]
],
[
[
17,
24,
808
],
[
808,
24,
1592
],
[
1592,
24,
512
]
],
[
[
17,
25,
888
],
[
888,
7,
7669
],
[
7669,
46,
512
]
]
] | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
],
[
"Iopromide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
],
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Iopanoic acid"
]
]
] | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid and Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Sotalol may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Iopanoic acid (Compound) |
DB09054 | DB11003 | 384 | 748 | [
"DDInter905",
"DDInter100"
] | Idelalisib | Anthrax vaccine | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
384,
24,
748
]
],
[
[
384,
63,
322
],
[
322,
24,
748
]
],
[
[
384,
64,
594
],
[
594,
24,
748
]
],
[
[
384,
25,
564
],
[
564,
63,
748
]
],
[
[
384,
24,
1619
],
[
1619,
63,
748
]
],
[
[
384,
24,
1480
],
[
1480,
24,
748
]
],
[
[
384,
25,
951
],
[
951,
24,
748
]
],
[
[
384,
63,
322
],
[
322,
63,
168
],
[
168,
24,
748
]
],
[
[
384,
63,
168
],
[
168,
24,
322
],
[
322,
24,
748
]
],
[
[
384,
64,
594
],
[
594,
25,
676
],
[
676,
63,
748
]
]
] | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may lead to a major life threatening interaction when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Idelalisib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00620 | DB09048 | 175 | 555 | [
"DDInter1855",
"DDInter1284"
] | Triamcinolone | Netupitant | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. | Moderate | 1 | [
[
[
175,
24,
555
]
],
[
[
175,
63,
1101
],
[
1101,
23,
555
]
],
[
[
175,
24,
283
],
[
283,
62,
555
]
],
[
[
175,
25,
384
],
[
384,
62,
555
]
],
[
[
175,
24,
473
],
[
473,
24,
555
]
],
[
[
175,
40,
1573
],
[
1573,
24,
555
]
],
[
[
175,
63,
1324
],
[
1324,
24,
555
]
],
[
[
175,
25,
676
],
[
676,
63,
555
]
],
[
[
175,
24,
159
],
[
159,
63,
555
]
],
[
[
175,
1,
617
],
[
617,
24,
555
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
]
] | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Netupitant
Triamcinolone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Netupitant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Triamcinolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Triamcinolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Netupitant |
DB00574 | DB00963 | 121 | 1,263 | [
"DDInter717",
"DDInter241"
] | Fenfluramine | Bromfenac | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Moderate | 1 | [
[
[
121,
24,
1263
]
],
[
[
121,
24,
935
],
[
935,
40,
1263
]
],
[
[
121,
63,
831
],
[
831,
40,
1263
]
],
[
[
121,
24,
1512
],
[
1512,
24,
1263
]
],
[
[
121,
24,
123
],
[
123,
63,
1263
]
],
[
[
121,
63,
702
],
[
702,
24,
1263
]
],
[
[
121,
25,
222
],
[
222,
63,
1263
]
],
[
[
121,
24,
1468
],
[
1468,
64,
1263
]
],
[
[
121,
63,
834
],
[
834,
25,
1263
]
],
[
[
121,
24,
126
],
[
126,
25,
1263
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} (Compound) resembles {v} (Compound)",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
]
]
] | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bromfenac (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Fenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Bromfenac
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Bromfenac
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Bromfenac |
DB04946 | DB09020 | 924 | 28 | [
"DDInter907",
"DDInter212"
] | Iloperidone | Bisacodyl | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
924,
24,
28
]
],
[
[
924,
63,
662
],
[
662,
1,
28
]
],
[
[
924,
63,
128
],
[
128,
40,
28
]
],
[
[
924,
18,
4046
],
[
4046,
57,
28
]
],
[
[
924,
21,
28666
],
[
28666,
60,
28
]
],
[
[
924,
25,
823
],
[
823,
63,
28
]
],
[
[
924,
25,
1250
],
[
1250,
24,
28
]
],
[
[
924,
64,
702
],
[
702,
24,
28
]
],
[
[
924,
63,
355
],
[
355,
24,
28
]
],
[
[
924,
1,
519
],
[
519,
24,
28
]
]
] | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} (Compound) downregulates {v} (Gene)",
"PIK3C2B"
],
[
"PIK3C2B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Iloperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
],
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
]
] | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine (Compound) resembles Bisacodyl (Compound)
Iloperidone (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) is downregulated by Bisacodyl (Compound)
Iloperidone (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Iloperidone may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Iloperidone may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Iloperidone may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Iloperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl |
DB00539 | DB01064 | 11 | 1,148 | [
"DDInter1837",
"DDInter987"
] | Toremifene | Isoprenaline | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Major | 2 | [
[
[
11,
25,
1148
]
],
[
[
11,
24,
480
],
[
480,
24,
1148
]
],
[
[
11,
6,
9842
],
[
9842,
45,
1148
]
],
[
[
11,
18,
6929
],
[
6929,
57,
1148
]
],
[
[
11,
21,
29316
],
[
29316,
60,
1148
]
],
[
[
11,
25,
1220
],
[
1220,
62,
1148
]
],
[
[
11,
64,
534
],
[
534,
24,
1148
]
],
[
[
11,
25,
1151
],
[
1151,
63,
1148
]
],
[
[
11,
25,
1052
],
[
1052,
24,
1148
]
],
[
[
11,
36,
675
],
[
675,
24,
1148
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"ITGAE"
],
[
"ITGAE",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
]
] | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Toremifene (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Isoprenaline (Compound)
Toremifene (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Isoprenaline (Compound)
Toremifene (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Isoprenaline (Compound)
Toremifene may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline
Toremifene may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Toremifene may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Toremifene may lead to a major life threatening interaction when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Toremifene (Compound) resembles Dextropropoxyphene (Compound) and Toremifene may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline |
DB00682 | DB04575 | 126 | 35 | [
"DDInter1951",
"DDInter1555"
] | Warfarin | Quinestrol | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
126,
24,
35
]
],
[
[
126,
24,
890
],
[
890,
1,
35
]
],
[
[
126,
63,
559
],
[
559,
1,
35
]
],
[
[
126,
25,
984
],
[
984,
40,
35
]
],
[
[
126,
63,
752
],
[
752,
23,
35
]
],
[
[
126,
24,
1264
],
[
1264,
23,
35
]
],
[
[
126,
24,
913
],
[
913,
63,
35
]
],
[
[
126,
24,
1042
],
[
1042,
24,
35
]
],
[
[
126,
23,
135
],
[
135,
63,
35
]
],
[
[
126,
63,
353
],
[
353,
24,
35
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Quinestrol (Compound)
Warfarin may lead to a major life threatening interaction when taken with Danazol and Danazol (Compound) resembles Quinestrol (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol |
DB00842 | DB08938 | 686 | 1,384 | [
"DDInter1359",
"DDInter1112"
] | Oxazepam | Magaldrate | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both [diazepam] and [temazepam] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
686,
23,
1384
]
],
[
[
686,
40,
1119
],
[
1119,
23,
1384
]
],
[
[
686,
24,
401
],
[
401,
23,
1384
]
],
[
[
686,
1,
905
],
[
905,
23,
1384
]
],
[
[
686,
40,
1119
],
[
1119,
24,
752
],
[
752,
23,
1384
]
],
[
[
686,
24,
401
],
[
401,
63,
556
],
[
556,
23,
1384
]
],
[
[
686,
40,
1565
],
[
1565,
63,
752
],
[
752,
23,
1384
]
],
[
[
686,
40,
1174
],
[
1174,
1,
1119
],
[
1119,
23,
1384
]
],
[
[
686,
40,
523
],
[
523,
23,
891
],
[
891,
23,
1384
]
],
[
[
686,
1,
905
],
[
905,
40,
1119
],
[
1119,
23,
1384
]
]
] | [
[
[
"Oxazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
]
] | Oxazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam (Compound) resembles Temazepam (Compound) and Temazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Oxazepam (Compound) resembles Lorazepam (Compound) and Lorazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Magaldrate |
DB00108 | DB06273 | 1,066 | 980 | [
"DDInter1268",
"DDInter1824"
] | Natalizumab | Tocilizumab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023. | Major | 2 | [
[
[
1066,
25,
980
]
],
[
[
1066,
23,
1114
],
[
1114,
62,
980
]
],
[
[
1066,
23,
1461
],
[
1461,
23,
980
]
],
[
[
1066,
25,
139
],
[
139,
24,
980
]
],
[
[
1066,
25,
975
],
[
975,
63,
980
]
],
[
[
1066,
24,
949
],
[
949,
63,
980
]
],
[
[
1066,
64,
66
],
[
66,
24,
980
]
],
[
[
1066,
24,
267
],
[
267,
24,
980
]
],
[
[
1066,
25,
1011
],
[
1011,
64,
980
]
],
[
[
1066,
25,
1531
],
[
1531,
25,
980
]
]
] | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
]
] | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Natalizumab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Natalizumab may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Natalizumab may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tocilizumab
Natalizumab may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab |
DB00844 | DB09272 | 314 | 412 | [
"DDInter1257",
"DDInter632"
] | Nalbuphine | Eluxadoline | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
314,
24,
412
]
],
[
[
314,
63,
1594
],
[
1594,
24,
412
]
],
[
[
314,
24,
830
],
[
830,
24,
412
]
],
[
[
314,
64,
475
],
[
475,
24,
412
]
],
[
[
314,
25,
407
],
[
407,
63,
412
]
],
[
[
314,
25,
593
],
[
593,
24,
412
]
],
[
[
314,
1,
560
],
[
560,
24,
412
]
],
[
[
314,
40,
421
],
[
421,
24,
412
]
],
[
[
314,
63,
1594
],
[
1594,
24,
1105
],
[
1105,
24,
412
]
],
[
[
314,
63,
543
],
[
543,
63,
1594
],
[
1594,
24,
412
]
]
] | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} (Compound) resembles {v} (Compound)",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
]
] | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline |
DB00731 | DB00881 | 1,144 | 954 | [
"DDInter1269",
"DDInter1554"
] | Nateglinide | Quinapril | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Quinapril was granted FDA approval on 19 November 1991. A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999. | Moderate | 1 | [
[
[
1144,
24,
954
]
],
[
[
1144,
74,
1638
],
[
1638,
1,
954
]
],
[
[
1144,
63,
610
],
[
610,
1,
954
]
],
[
[
1144,
1,
11242
],
[
11242,
1,
954
]
],
[
[
1144,
24,
664
],
[
664,
1,
954
]
],
[
[
1144,
63,
1523
],
[
1523,
40,
954
]
],
[
[
1144,
40,
766
],
[
766,
1,
954
]
],
[
[
1144,
6,
7870
],
[
7870,
45,
954
]
],
[
[
1144,
21,
28734
],
[
28734,
60,
954
]
],
[
[
1144,
63,
251
],
[
251,
24,
954
]
]
] | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound)",
"Aspartame"
],
[
"Aspartame",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
],
[
"Perindopril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound)",
"Ramipril"
],
[
"Ramipril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"SLC15A2"
],
[
"SLC15A2",
"{u} (Gene) is bound by {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Immune system disorder"
],
[
"Immune system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinapril"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
]
] | Nateglinide (Compound) resembles Trandolapril (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Quinapril (Compound)
Nateglinide (Compound) resembles Aspartame (Compound) and Aspartame (Compound) resembles Quinapril (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril (Compound) resembles Quinapril (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Quinapril (Compound)
Nateglinide (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Quinapril (Compound)
Nateglinide (Compound) binds SLC15A2 (Gene) and SLC15A2 (Gene) is bound by Quinapril (Compound)
Nateglinide (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Quinapril (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril |
DB01577 | DB12500 | 1,529 | 283 | [
"DDInter1161",
"DDInter714"
] | Metamfetamine | Fedratinib | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1529,
24,
283
]
],
[
[
1529,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1529,
24,
761
],
[
761,
24,
283
]
],
[
[
1529,
64,
1039
],
[
1039,
24,
283
]
],
[
[
1529,
24,
1670
],
[
1670,
25,
283
]
],
[
[
1529,
63,
1419
],
[
1419,
23,
271
],
[
271,
23,
283
]
],
[
[
1529,
24,
761
],
[
761,
24,
351
],
[
351,
23,
283
]
],
[
[
1529,
63,
401
],
[
401,
24,
271
],
[
271,
23,
283
]
],
[
[
1529,
63,
1411
],
[
1411,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1529,
63,
473
],
[
473,
24,
466
],
[
466,
62,
283
]
]
] | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
]
] | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib |
DB01105 | DB02959 | 222 | 871 | [
"DDInter1665",
"DDInter1362"
] | Sibutramine | Oxitriptan | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication of major depression under trade names like Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. Several double-blind placebo-controlled clinical trials have demonstrated the effectiveness of 5-HTP in the treatment of depression, though a lack of high quality studies has been noted. More study is needed to determine efficacy in treating depression. | Major | 2 | [
[
[
222,
25,
871
]
],
[
[
222,
63,
13
],
[
13,
24,
871
]
],
[
[
222,
25,
1053
],
[
1053,
25,
871
]
],
[
[
222,
64,
121
],
[
121,
25,
871
]
],
[
[
222,
25,
1629
],
[
1629,
64,
871
]
],
[
[
222,
63,
13
],
[
13,
63,
475
],
[
475,
24,
871
]
],
[
[
222,
63,
475
],
[
475,
24,
13
],
[
13,
24,
871
]
],
[
[
222,
25,
1053
],
[
1053,
25,
1191
],
[
1191,
1,
871
]
],
[
[
222,
25,
1264
],
[
1264,
23,
1191
],
[
1191,
1,
871
]
],
[
[
222,
64,
121
],
[
121,
63,
1152
],
[
1152,
1,
871
]
]
] | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"Oxitriptan"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Oxitriptan"
]
]
] | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan
Sibutramine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Oxitriptan
Sibutramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Oxitriptan
Sibutramine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Oxitriptan
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan
Sibutramine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Levodopa and Levodopa (Compound) resembles Oxitriptan (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Levodopa and Levodopa (Compound) resembles Oxitriptan (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Oxitriptan (Compound) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.